“As our client for the past two years, Scott has been an absolute pleasure to work with in the oncology/hematology space. He is an exceptional communicator who clearly leads his team in achieving the company's strategic goals, while also being responsive to outside partners like ourselves. I am fortunate to have met Scott and work with him.”
About
✔Strategy ✔Change Leadership ✔Commercial Innovation ✔Execution ✔Global M&A
Proven…
Activity
-
Great to see continued commitment to rare disease patients! Great leadership by Matt Flesch and his team!
Great to see continued commitment to rare disease patients! Great leadership by Matt Flesch and his team!
Liked by Scott Megaffin
-
We're in London at the #ESCCongress, connecting with the global #Cardiovascular community. Excited to engage in conversations that push the…
We're in London at the #ESCCongress, connecting with the global #Cardiovascular community. Excited to engage in conversations that push the…
Liked by Scott Megaffin
-
You don't have to go to college to have a great career. We need more vocational training in high school.
You don't have to go to college to have a great career. We need more vocational training in high school.
Liked by Scott Megaffin
Experience
Volunteer Experience
-
Board of Trustee
Hopewell Public Library
- 7 years
Publications
-
Pharmacoeconomic - Addendum - 9 Publications
High Unmet Need - Myleodyplastic Syndrome - Hematologic Malignancy
Cogle CR, Mukherjee S, Megaffin S, et al.
Cost Effectiveness of Treatments after Failure of a First-Line Hypomethylating Agent in Myelodysplastic Syndromes (MDS). Blood. 2014;124(21):1928-1928.
Cogle CR, Ortendahl JD, Bentley TG, Megaffin S, et al.
Cost–effectiveness of treatments for high-risk myelodysplastic syndromes after failure of first-line hypomethylating agent therapy. Expert Review of Pharmacoeconomics & Outcomes Research. 2016;16(2):275-284…Cogle CR, Mukherjee S, Megaffin S, et al.
Cost Effectiveness of Treatments after Failure of a First-Line Hypomethylating Agent in Myelodysplastic Syndromes (MDS). Blood. 2014;124(21):1928-1928.
Cogle CR, Ortendahl JD, Bentley TG, Megaffin S, et al.
Cost–effectiveness of treatments for high-risk myelodysplastic syndromes after failure of first-line hypomethylating agent therapy. Expert Review of Pharmacoeconomics & Outcomes Research. 2016;16(2):275-284. doi:10.1586/14737167.2016.1096200.
Cogle CR, Mukherjee S, Bentley TG, Megaffin S, et al.
Healthcare Resource Utilization and Costs Among Patients with Myelodysplastic Syndrome Who Failed 1st-Line Therapy. Blood. 2014;124(21):2627-2627.
Cogle CR, Kurtin SE, Bentley TG, Megaffin S, et al. Incidence of First-Line and Second-Line Myelodysplastic Syndrome in a US Commercial Claims Database. Blood. 2014;124(21):6008-6008.
Bentley T, Broder M, Megaffin S, et al.
MDS Conceptual Framework Identifies Unmet Need for HMA-Unresponsive and Transplant-Ineligible Patients. Leukemia Research. 2015;39:S101. doi:10.1016/S0145-2126(15)30204-6.
Cogle C, Kurtin S, Bentley T, Megaffin S, et al.
Population Incidence of MDS Following Hypomethylating Agent (HMA) Treatment Failure: Analysis of US Commercial Claims Data. Leukemia Research. 2015;39:S37. doi:10.1016/S0145-2126(15)30077-1.
Cogle CR, Kurtin SE, Bentley TGK, Megaffin S, et al.
The Incidence and Health Care Resource Burden of the Myelodysplastic Syndromes in Patients in Whom First‐Line Hypomethylating Agents Fail. The Oncologist. 2017;22(4):379-385. doi:10.1634/theoncologist.2016-0211.
Mukherjee S, Cogle CR, Bentley TG, Megaffin S, et al.
Treatment Patterns Among Patients with Myelodysplastic Syndromes: Observations of 1st-Line Therapy, Discontinuation and the Need of Additional Therapies.Blood. 2014;124(21):2598-2598.
Organizations
-
Bio New Jersey
Legislative Committee, 2015 – Present | Business Development & Investment Committee, 2010 – 2014 | Finance & CFO Committee, 2010 – Present
Legislative Committee, 2015 – Present Business Development & Investment Committee, 2010 – 2014 Finance & CFO Committee, 2010 – Present
-
Pennsylvania Bio | Life Sciences PA
Legislative Committee, 2015 – Present | Finance & CFO Committee, 2010 – Present
Recommendations received
1 person has recommended Scott
Join now to viewMore activity by Scott
-
Thank you very much to APC - Paul, Colin and Michelle - for the great collaboration over the years!
Thank you very much to APC - Paul, Colin and Michelle - for the great collaboration over the years!
Liked by Scott Megaffin
-
We are pleased to announce that our via our Forbion Growth Opportunities Fund II, we have co-led a $100M Series A financing round for Navigator…
We are pleased to announce that our via our Forbion Growth Opportunities Fund II, we have co-led a $100M Series A financing round for Navigator…
Liked by Scott Megaffin
-
This #NationalDogDay we’re excited to shine a spotlight on the behind-the-scenes stars of the iECURE team! Here’s to the dogs who make our workdays…
This #NationalDogDay we’re excited to shine a spotlight on the behind-the-scenes stars of the iECURE team! Here’s to the dogs who make our workdays…
Liked by Scott Megaffin
-
"GPCR targeting represents approximately 35% of all approved drugs and account for neurological indications such as ..." A true leap forward in MOA…
"GPCR targeting represents approximately 35% of all approved drugs and account for neurological indications such as ..." A true leap forward in MOA…
Shared by Scott Megaffin
-
Congratulations to the team, led by Susan Acton and Laurent Chesnel, PhD in collaboration with Michelle O' Donnell, Paul Ross, and Colin Hill -…
Congratulations to the team, led by Susan Acton and Laurent Chesnel, PhD in collaboration with Michelle O' Donnell, Paul Ross, and Colin Hill -…
Shared by Scott Megaffin
-
I am thrilled for our team at PHAR (Partnership for Health Analytic Research) (Partnership for Health Analytic Research) to become part of the…
I am thrilled for our team at PHAR (Partnership for Health Analytic Research) (Partnership for Health Analytic Research) to become part of the…
Liked by Scott Megaffin
-
Today, I’m thrilled to celebrate 8 remarkable years with Calcium+Company. It’s been an incredible journey, witnessing and contributing to our…
Today, I’m thrilled to celebrate 8 remarkable years with Calcium+Company. It’s been an incredible journey, witnessing and contributing to our…
Liked by Scott Megaffin
-
Foundations Commercial Real Estate is thrilled to introduce you to our fall intern, Michael Jankovich! He will join the team later this month, and…
Foundations Commercial Real Estate is thrilled to introduce you to our fall intern, Michael Jankovich! He will join the team later this month, and…
Liked by Scott Megaffin
-
“The tyranny of Communism is as old as the Pharaohs and the Pyramids — that the State stands above all men and their individual aspirations.”…
“The tyranny of Communism is as old as the Pharaohs and the Pyramids — that the State stands above all men and their individual aspirations.”…
Liked by Scott Megaffin
-
You've been there: stuck in the tedium of feasibility projections and time-consuming analysis. That's why we developed VISIONAL™, our innovative…
You've been there: stuck in the tedium of feasibility projections and time-consuming analysis. That's why we developed VISIONAL™, our innovative…
Liked by Scott Megaffin
-
It was great to speak with Augusta University and Medical College of Georgia at Augusta University faculty innovators and to explore ways the…
It was great to speak with Augusta University and Medical College of Georgia at Augusta University faculty innovators and to explore ways the…
Liked by Scott Megaffin
-
9 years after starting our biotech, on Friday we completed the sale of the company to Eli Lilly, who will advance our therapy in late clinical trials…
9 years after starting our biotech, on Friday we completed the sale of the company to Eli Lilly, who will advance our therapy in late clinical trials…
Liked by Scott Megaffin
Other similar profiles
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore MoreOthers named Scott Megaffin
1 other named Scott Megaffin is on LinkedIn
See others named Scott Megaffin